{"id":"aphd-012","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of genital yeast infections"},{"rate":"null","effect":"Increased risk of urinary tract infections"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting the SGLT2 receptor, APHD-012 reduces glucose reabsorption in the kidneys, leading to decreased blood glucose levels. This mechanism is particularly useful in the treatment of type 2 diabetes.","oneSentence":"APHD-012 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:10:02.795Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT05737927","phase":"PHASE1","title":"Pharmacodynamics and Pharmacokinetics of Different Glucose Bead Formulations in Obese Healthy Subjects","status":"COMPLETED","sponsor":"Aphaia Pharma US LLC","startDate":"2020-09-16","conditions":"Obese","enrollment":20},{"nctId":"NCT07008456","phase":"PHASE2","title":"A Study to Investigate the Efficacy and Safety of Two Different Doses of Twice Daily Distal Jejunal-release Dextrose Beads Formulations Combined With a Gel Composition Compared to Placebos in Obese Subjects With Weight Related Comorbidities","status":"RECRUITING","sponsor":"Aphaia Pharma US LLC","startDate":"2025-09-12","conditions":"Obese With Comorbidities, Obese Patients (BMI ≥ 30 kg/m²)","enrollment":102},{"nctId":"NCT05803772","phase":"PHASE2","title":"A Study to Evaluate Efficacy and Safety of Distal Jejunal-release Dextrose Beads Formulation in Subjects With a Pathological Oral Glucose Tolerance Test","status":"COMPLETED","sponsor":"Aphaia Pharma US LLC","startDate":"2023-03-31","conditions":"PreDiabetes, Glucose Tolerance Impaired","enrollment":31},{"nctId":"NCT05385978","phase":"PHASE2","title":"A Study of Distal Jejunal-release Dextrose in Obese Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Aphaia Pharma US LLC","startDate":"2022-11-01","conditions":"Obese","enrollment":150}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Distal jejunal-release dextrose beads"],"phase":"phase_2","status":"active","brandName":"APHD-012","genericName":"APHD-012","companyName":"Aphaia Pharma US LLC","companyId":"aphaia-pharma-us-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"APHD-012 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}